Pathogenesis and treatment of renal failure in multiple myeloma.
about
Does my patient with a serum monoclonal spike have multiple myeloma?Venous and arterial thrombotic risks with thalidomide: evidence and practical guidanceCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsThe efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.Bortezomib in patients with renal impairment.Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment.Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).Pathogenesis of renal failure in multiple myeloma: any role of contrast media?The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone.Spotlight on lenalidomide in relapsed or refractory multiple myeloma.Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.Sleep measured by polysomnography in patients receiving high-dose chemotherapy for multiple myeloma prior to stem cell transplantation.The use of novel agents in the treatment of relapsed and refractory multiple myelomaChanges in renal function after different tandem hematopoietic stem-cell transplantation approaches in patients with multiple myeloma.Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity scoreDetermination of intrarenal resistance index (RI) in patients with multiple myeloma.European Myeloma Network guidelines for the management of multiple myeloma-related complications.Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases.Treatment of multiple myeloma: a comprehensive review.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.Management of myeloma-associated renal dysfunction in the era of novel therapies.Current treatments for renal failure due to multiple myeloma.Kidney disease and multiple myeloma.International Myeloma Working Group recommendations for global myeloma care.Therapeutic apheresis for patients with cancer.Onco-nephrology: current concepts and future perspectives.Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment.Managing multiple myeloma in elderly patients.Molecular mechanisms, current management and next generation therapy in myeloma bone disease.Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
P2860
Q26821981-B051E02C-4E15-4046-9B48-E8C87D91572BQ27008491-C8B177AF-C3AC-4E4D-B7AB-DA3B58F9CE54Q28084683-F58238DA-FEBE-4B94-9995-3BEF7191BD77Q33390284-F46A5CA2-7656-471D-B120-2CDA22285EE2Q33396250-A7A5616F-83E7-440E-85B6-1B8B68C9FE8FQ33398587-30D17778-92D8-4204-89B6-949183210F62Q33400871-5366D6A0-E7CA-4580-BD9E-5DD4DF49E71AQ33407105-AC0A8940-3CB1-4A89-9899-D93B8768AD61Q33418389-1393AC1D-5451-4FD3-BA31-C8EDD897248AQ33421008-C7CE6DA2-3C15-4523-8DC4-9B8D75A6C8B0Q33442039-986E0627-38F1-480B-9395-C075E29E011BQ33616884-B0F75D69-03EC-41B4-AF4E-747F76BF6191Q33864162-475C648B-5365-4500-84F2-C596156A5158Q33874209-57EB4814-8FB4-4C9D-A1FE-76C12496BEAAQ34028642-8519429C-13A3-4DDE-99CE-B170D350C5C0Q35012436-5B4706C2-06BE-45B1-8D41-4039C4F5E18CQ35072925-F8DE9025-039B-4779-987D-4B86CB3307E5Q35097319-9D857405-3A64-455B-8807-CC4811C14702Q35333741-184EA046-D267-4F08-8F09-946EC25BBFC8Q35603608-E259F609-AA17-4E17-8B15-BBAA9C99774AQ35664302-75FD7E9D-A0CA-42D6-BCEE-C11D67990D63Q35959247-8B6FF9CC-C8E7-42A2-9A60-5A10D4599FAEQ36115636-F42C7C34-C962-455C-A821-4091301104F3Q36209159-E23EB810-F8E0-4751-8CA6-05E786D49551Q36443263-B521C45A-8008-4C03-BACE-E0D3AF3F69C6Q37542173-30C68C2D-D9EF-4CAE-88C4-502450BC5A53Q37697253-4EDBF3FB-2FE0-475F-A9B9-60519C370912Q37761370-9271D2B5-5B17-4A1E-A37E-8BA9957DAD15Q37835695-CB67DB41-6B1E-4C29-9742-B377B20D3C98Q37858523-E4C90B1A-D7DA-4E3D-8FD1-DBB6FCFD723CQ37978343-08C628E0-6D44-46D2-99EF-7B6C4CA9E72DQ38109235-53E7E37B-5D92-4DC4-83AD-07E1F47EEB24Q38122674-B6C19A90-E207-4128-99CD-5A6CB03CEAE0Q38157532-083B9D15-5E44-4F32-97FC-CB09B07BA3D5Q38287610-7EE51D1F-CCFF-41FF-9B43-AAE92172C0B0Q38382457-35DFDB90-6772-4A00-A351-8C09495B3816Q38466621-86A2D23E-8CFA-46D0-B595-14B27548351CQ38605484-633C3B4D-8B4D-4817-982B-32C89D66376FQ38749233-960D855B-F9EC-4CFD-B38A-789D96A088BEQ38757067-F291A343-A467-418B-9765-D363945F96FA
P2860
Pathogenesis and treatment of renal failure in multiple myeloma.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pathogenesis and treatment of renal failure in multiple myeloma.
@ast
Pathogenesis and treatment of renal failure in multiple myeloma.
@en
Pathogenesis and treatment of renal failure in multiple myeloma.
@nl
type
label
Pathogenesis and treatment of renal failure in multiple myeloma.
@ast
Pathogenesis and treatment of renal failure in multiple myeloma.
@en
Pathogenesis and treatment of renal failure in multiple myeloma.
@nl
prefLabel
Pathogenesis and treatment of renal failure in multiple myeloma.
@ast
Pathogenesis and treatment of renal failure in multiple myeloma.
@en
Pathogenesis and treatment of renal failure in multiple myeloma.
@nl
P2093
P356
P1433
P1476
Pathogenesis and treatment of renal failure in multiple myeloma.
@en
P2093
P2888
P304
P356
10.1038/LEU.2008.131
P577
2008-06-05T00:00:00Z
P5875
P6179
1053102118